Pregled bibliografske jedinice broj: 133318
Cytochrome P450 - CYP2C9 Genotyping in Warfarin Drug Therapy Optimization
Cytochrome P450 - CYP2C9 Genotyping in Warfarin Drug Therapy Optimization // The third European-American school in forensic genetics and Mayo clinic course in advanced molecular and cellular medicine - Final program and abstracts / Primorac, D. ; Erceg Ivkošić, I. ; Ivkošić, A . ; Vuk-Pavlović, S. ; Schanfield, M. (ur.).
Zagreb: Studio Hrg, 2003. str. 114-114 (poster, nije recenziran, sažetak, znanstveni)
CROSBI ID: 133318 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Cytochrome P450 - CYP2C9 Genotyping in Warfarin Drug Therapy Optimization
Autori
Štefanović, Mario ; Topić, Elizabeta ; Samardžija, Marina ; Šimundić, Ana-Maria ; Begonja, Antonija
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
The third European-American school in forensic genetics and Mayo clinic course in advanced molecular and cellular medicine - Final program and abstracts
/ Primorac, D. ; Erceg Ivkošić, I. ; Ivkošić, A . ; Vuk-Pavlović, S. ; Schanfield, M. - Zagreb : Studio Hrg, 2003, 114-114
Skup
The third European-American school in forensic genetics and Mayo clinic course in advanced molecular and cellular medicine
Mjesto i datum
Zagreb, Hrvatska, 01.09.2003. - 05.09.2003
Vrsta sudjelovanja
Poster
Vrsta recenzije
Nije recenziran
Ključne riječi
CYP2C9; warfarin; anticoagulant therapy
Sažetak
S– warfarin is an anticoagulant therapy drug and its often unpredictable dose response results at least in part due to genetic differences in CYP2C9 enzyme metabolic capacity. Besides wild type- CYP2C9*1, there are mutant alleles CYP2C9*2 and CYP2C9*3 that in homozygotes code enzymes with activities of only 16-20% and 5% of total wild type activity, respectively. Our aim was to investigate the possibility of warfarin dosage prediction by CYP2C9 polymorphism genotyping. We genotyped 181 patients (43.6 % males, mean age 60.2 ; SD=14.5) by PCR-RFLP method as reported by Nasu K. et al., 1997. Patients were receiving warfarin in doses needed for maintaining prothrombin time within INR range 1.5-2.5. Results showed significantly higher warfarin mean daily dose (DD) among 104 wild type homozygous patients (DD=4.4mg ; SD=1.9) compared to 77 patients with at least one mutated allele (DD= 3.7mg ; SD 1.7, p=0.010) and 10 patients with both mutant alleles (DD=2.6mg ; SD=1.4, p=0.004). Patients were also divided into groups according to warfarin median daily dose: among DD<4.1mg group (90 patients), we found 71% wild type (1*), and 29% mutated (2* and 3*) alleles. These 2* and 3* allelic frequencies were significantly higher (p=0.027) than in DD>4.1mg group (91 patients) (81% wild type (1*), and 19% mutated (2* and 3*) alleles). Genotype frequencies did not differ significantly. Results of our investigation are concordant to other author's findings and suggest a relationship of CYP2C9 defective alleles with lower warfarin doses. Therefore, CYP2C9 genotyping could be of predicting and optimizing importance in anticoagulant drug therapy.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
